Current and Future Medications for Hepatitis C (cont.)
Various pharmaceutical companies are conducting clinical research determine efficacy and safety use of their novel compound sin treating hepatitis C in the near future per FDA approval:
- BI 201335 and BI 207127 (Boehringer Ingelheim Pharmaceuticals) are being developed for the treatment of chronic HCV infection. BI 201335 and BI 207127 work by preventing the virus from replicating.
- Thymosin alpha-1 (Zadaxin, by SciClone) is a protein that enhances the body's immune system to counteract viruses. Research is being done to determine the efficacy and safety of thymosin alpha-1 in combination with peg-interferon alfa- 2a and ribavirin for the therapy of chronic hepatitis C nonresponsive to the combination of IFN and ribavirin
- ISIS 14803 (Isis Pharmaceuticals and Elan) is a nucleoside analog that disrupts the production of viral proteins during viral cell division, thereby decreasing the ability of HCV to multiplyABT450/r and ABT 267 (Abbott Pharmaceuticals) are being studied in combination with peginterferon alpha-2a and ribavirin in patients with HCV who did not respond to treatment in a previous study of standard combination therapy
- Other interferons are being investigated, including recombinant interferon beta-1a (Serono Lab), omega interferon (BioMedicines), and VX-497 (Vertex Pharmaceuticals).
Medical and Pharmacy Editor:
Must Read Articles Related to Current and Future Medications for Hepatitis C
Hepatitis C is inflammation of the liver caused by infection with the hepatitis C virus. Hepatitis C is contagious. Symptoms of hepatitis include fatigue, abdom...learn more >>
Currently, more than 17,000 people in the United States are waiting for liver transplants. According to the United Network for Organ Sharing (UNOS), about 5,300...learn more >>